| Abstrakt: |
Outcome Capital, a specialized investment banking firm that serves middle market growth companies in the life science and technology segments, today announced that Meridian Bioscience, a provider of diagnostic testing solutions and life science raw materials, has acquired GenePOC’s molecular diagnostics business portfolio. Meridian has agreed to make a cash payment at closing of the transaction of $50 million with future payments totaling up to an additional $70 million contingent upon the successful achievement of certain technical development milestones and sales thresholds. Outcome Capital served as the exclusive strategic and financial advisor to GenePOC for the transaction. [ABSTRACT FROM PUBLISHER] |
